Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $40.00

Denali Therapeutics (NASDAQ:DNLI) had its target price increased by The Goldman Sachs Group from $35.00 to $40.00 in a report issued on Thursday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

A number of other brokerages also recently weighed in on DNLI. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a research note on Monday, March 2nd. Wedbush dropped their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Morgan Stanley reissued an “overweight” rating and set a $40.00 target price on shares of Denali Therapeutics in a research note on Thursday, January 8th. Finally, UBS Group started coverage on shares of Denali Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.82.

Denali Therapeutics Stock Down 8.0%

DNLI opened at $18.16 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16. The company has a market capitalization of $2.88 billion, a PE ratio of -6.11 and a beta of 1.02. The stock’s fifty day moving average is $20.43 and its 200-day moving average is $17.85. Denali Therapeutics has a one year low of $10.57 and a one year high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period in the prior year, the firm posted ($0.67) EPS. On average, equities analysts predict that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the sale, the chief executive officer owned 296,833 shares in the company, valued at approximately $4,897,744.50. The trade was a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently made changes to their positions in the company. Groupama Asset Managment lifted its position in shares of Denali Therapeutics by 11.7% in the 4th quarter. Groupama Asset Managment now owns 151,591 shares of the company’s stock valued at $2,503,000 after acquiring an additional 15,833 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Denali Therapeutics by 28.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after purchasing an additional 1,615,565 shares in the last quarter. Invesco Ltd. grew its position in Denali Therapeutics by 17.0% during the 4th quarter. Invesco Ltd. now owns 291,936 shares of the company’s stock worth $4,820,000 after purchasing an additional 42,469 shares in the last quarter. Vestal Point Capital LP acquired a new stake in Denali Therapeutics during the 4th quarter valued at $7,677,000. Finally, Virtus Investment Advisers LLC raised its stake in Denali Therapeutics by 94.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 14,795 shares of the company’s stock valued at $244,000 after purchasing an additional 7,171 shares during the period. Institutional investors and hedge funds own 92.92% of the company’s stock.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.